Sector Expert: Andrew Gengos
Andrew Gengos joined ImmunoCellular Therapeutics as president and CEO in December 2012. Spanning more than 20 years in the life science industry, his experience includes executive leadership positions in both large and emerging companies. He has broad expertise in corporate strategy, business development and transactions, including mergers and acquisitions, financing, operations, commercial planning and healthcare policy. Gengos was most recently the president and CEO of Neuraltus Pharmaceuticals, where he led implementation of the company's clinical, regulatory, fundraising and business development strategies while operating the company on a virtual business model. Previously, he served for more than seven years with Amgen where, as vice president, strategy and corporate development, he managed the company's worldwide in-and-outbound business development activities, including acquisitions, licensing, spinouts, divestitures, corporate venture capital investments and alliance management. Before joining Amgen, Gengos was vice president, CFO and chief business officer of Dynavax Technologies, where he led the company's business functions, including finance and accounting, fundraising, budgeting, planning and business development. Earlier in his career, Gengos served as vice president, strategy at Chiron Corp. and as senior engagement manager at McKinsey & Co. Gengos holds a master's degree in business administration from the Anderson School of Business at the University of California, Los Angeles, and a bachelor's degree in chemical engineering from the Massachusetts Institute of Technology.
An Immunotherapeutic Approach to Glioblastoma: ImmunoCellular Therapeutics' CEO Andrew Gengos (12/16/15)
Los Angeles-based ImmunoCellular Therapeutics Ltd. is on the verge of a pivotal Phase 3 trial with its dendritic cell immunotherapy for brain cancer. It's an extraordinary and exciting time for CEO Andrew Gengos, who is a veteran biotech executive. In this interview with The Life Sciences Report, Gengos discusses his firm's recently reported Phase 2 data in glioblastoma, as well as the company's strategy for the upcoming registration trial.